EUCTR2007-002693-66-DE进行中（未招募）1 期
An Open-Label 5-Year 2nd Extension for 5 years to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.0 个研究点目标入组 16,071 人开始时间: 2007年11月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16,071
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Patient is a woman and is = 65 years of age on the day of signing informed consent.
- •2.Patient meets one of the following:
- •a)Patient is a candidate for osteoporosis therapy (bisphosphonates, strontium, or PTH), has BMD T-score =-1.5 at either the total hip or femoral neck site, BMD T-score =-4.0 at both sites, and has one prior vertebral fracture (defined as anterior, mid or posterior height loss of >20%). – OR-
- •b)Patient is a candidate for osteoporosis therapy (bisphosphonates, strontium, or PTH), has BMD T-score =-2.5 at either the total hip or femoral neck site, BMD T-score =-4.0 at both sites, and does not have a prior vertebral fracture (defined as anterior, mid or posterior height loss of >20%). – OR -
- •c)Patient is not a suitable candidate for, or has declined osteoporosis therapy (bisphosphonates, strontium, or PTH), has BMD T-score =-1.5 at either the total hip or femoral neck site, and has at least one prior vertebral fracture (defined as anterior, mid or posterior height loss of >20%). – OR-
- •d)Patient is not a suitable candidate for, or has declined osteoporosis therapy (bisphosphonates, strontium, or PTH), and has a BMD T-score =-2.5 at either the total hip or femoral neck site.
- •3.The patient has at least one hip that is evaluable by DXA (e.g., contains no hardware from orthopedic procedures).
- •4.Patient has been postmenopausal for at least 5 years, defined as no menses for at least 5 years OR at least 5 years status post bilateral oophorectomy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Patient has chosen treatment with oral bisphosphonates or other agents demonstrated to reduce the risk of hip fracture.
- •2)Patient has had a prior hip fracture.
- •3)Patient experienced a clinical fragility fracture (including a clinical vertebral fracture) within 24 months. (Note: Finger, toe, and skull fractures should not be considered with regard to this exclusion criterion.)
- •4)Patient has had more than 1 prior vertebral fracture, as defined in Inclusion Criterion 1 above, and she is a suitable candidate for osteoporosis therapy (i.e., bisphosphonates, strontium, or PTH).
- •5)Patient has or has had evidence of a metabolic bone disorder other than osteoporosis.
研究者
相似试验
进行中（未招募）
1 期
/APostmenopausal OsteoporosisMedDRA version: 18.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-002693-66-BGMerck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.16,071
进行中（未招募）
1 期
A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumPostmenopausal OsteoporosisEUCTR2011-005514-10-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254
进行中（未招募）
1 期
Extension to the Odanacatib Fracture Trial (PN018)MedDRA version: 17.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersosteoporosisEUCTR2014-002587-33-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.16,071
进行中（未招募）
1 期
An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254
已完成
不适用
A 5-YEAR OPEN LABEL EXTENSION TO: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF ODANACATIB (MK-0822) IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSISPER-075-10MERCK SHARP & DOHME PERU S.R.L.,3